Company / Shareholders' Equity
Amphstar Pharmaceuticals, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$788.8M
FY2025
5-year range
$445.5M / $788.8M
FY2021-FY2025
Trend
+7.7%
vs FY2024
Sector context
#56 of 213
Health Care
What the data says
At $789M, Amphstar Pharmaceuticals, Inc.'s shareholders' equity ranks #56 of 213 in the Health Care sector. Shareholders' Equity has increased for 7 consecutive years, from $332M in FY2018 to $789M in FY2025.
Based on SEC 10-K filings.
$789M in FY2025 with a 5-year CAGR of +14.4%.
Improved from $639M to $789M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +14.3%
- 5-Year CAGR
- +14.4%
- 10-Year CAGR
- -
Sector benchmark
#56 of 213 in Health CareTop 26% of 213This company $788.8M Sector average $2.5B
▼
-69.1% below sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s shareholders' equity has grown for 7 consecutive years.
- 5-year CAGR of +14.4%, indicating consistent growth.
- In FY2025, shareholders' equity increased 7.7% year-over-year.
- Ranks #56 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $788.8M | +7.7% |
| FY2024 | $732.3M | +14.5% |
| FY2023 | $639.4M | +21.0% |
| FY2022 | $528.7M | +18.7% |
| FY2021 | $445.5M | +10.7% |
| FY2020 | $402.3M | +5.5% |
| FY2019 | $381.4M | +14.7% |
| FY2018 | $332.4M | -0.4% |
| FY2017 | $333.7M | +1.4% |
| FY2016 | $329.3M | +11.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026